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Abstract
There is a growing interest in understanding the binding kinetics of compounds that bind to G protein-coupled receptors prior to
progressing a lead compound into clinical trials. Thewidely expressed adenosineA3 receptor (A3AR) has been implicated in a range of
diseases including immune conditions, and compounds that aim to selectively target this receptor are currently under development for
arthritis. Kinetic studies at the A3AR have been performed using a radiolabelled antagonist, but due to the kinetics of this probe, they
have been carried out at 10 °C inmembrane preparations. In this study, we have developed a live cell NanoBRET ligand binding assay
using fluorescent A3AR antagonists to measure kinetic parameters of labelled and unlabelled compounds at the A3AR at physiological
temperatures. The kinetic profiles of four fluorescent antagonists were determined in kinetic association assays, and it was found that
XAC-ser-tyr-X-BY630 had the longest residence time (RT = 288 ± 62 min) at the A3AR. The association and dissociation rate
constants of three antagonists PSB-11, compound 5, and LUF7565 were also determined using two fluorescent ligands (XAC-ser-
tyr-X-BY630 or AV039, RT = 6.8 ± 0.8 min) as the labelled probe and compared to those obtained using a radiolabelled antagonist
([3H]PSB-11, RT = 44.6 ± 3.9 min). There was close agreement in the kinetic parameters measured with AV039 and [3H]PSB-11 but
significant differences to those obtained using XAC-S-ser-S-tyr-X-BY630. These data indicate that selecting a probe with the appro-
priate kinetics is important to accurately determine the kinetics of unlabelled ligands with markedly different kinetic profiles.
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Introduction
The nucleoside adenosine is a ubiquitous signalling molecule
which modulates cellular responses to stress. Upon cellular
stress caused by mechanical, inflammatory or hypoxic
stressors, high concentrations of ATP are released [1, 2] which
are rapidly hydrolysed to adenosine [3]. Adenosine signals via
four related family A G protein-coupled receptors (GPCRs)
[4] of which the adenosine A3 receptor (A3AR) is thought to
play an important role in the control of infection and related
inflammation due to its expression on immune cells [5]. It has
also been proposed to play a cardio- [6, 7] and neuro-
protective [8, 9] role. In addition, the A3AR receptor has been
shown to be expressed in a variety of cancer cell lines, and
since the tumour micro-environment is often hypoxic, it may
play a role in tumour progression [10] . This has led to an
interest in developing molecules that target the A3AR in the
treatment of immune conditions and cancer [11].
In recent years, many molecules targeting GPCRs, includ-
ing those acting at adenosine receptors [12], have exhibited a
lack of efficacy in clinical trials [13]. The optimization of
molecules for clinical trials has historically focused on devel-
oping a candidate with high affinity and selectivity for the
target receptor, and these parameters are often measured at
equilibrium in model cell systems over-expressing the recep-
tor of interest [14, 15]. Within the last 10 years, it has become
clear that measuring the binding properties of a molecule at
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equilibrium may not be the most effective way to determine
potential in vivo efficacy and that determining the duration of
protein-drug interactions may be a better predictor of in vivo
action [16, 17]. As the equilibrium dissociation constant (Kd)
of a ligand at a GPCR is a function of the ligand’s association
(kon) and dissociation rate (koff) constants (Kd = koff/kon), mol-
ecules that have the same measured KD at equilibrium can
have markedly different kon and koff rate constants. To address
this, Copeland et al. (2006) introduced the concept residence
time (RT), which is the reciprocal of the dissociation rate
constant (RT = 1/koff), as a measure of the duration of drug-
target complex formation [18]. Depending on the clinical set-
ting, different RTs may be required. For example, drugs with a
long RT are preferred when an extended duration of action is
required and can reduce administration to once a day. This has
been demonstrated for the M3 muscarinic receptor antagonist
tiotropium and the β2 adrenoceptor agonist olodaterol which
both have long RTs and are once a day bronchodilators used to
treat chronic obstructive pulmonary disease [14, 19, 20]. Short
RT ligands are advantageous when the rapid, i.e. seconds to
minutes, replacement of the drug by an endogenous ligand is
crucial to avoid long-term side effects which has been pro-
posed to be the case for drugs targeting the dopamine D2
receptor [17, 21, 22].
A variety of techniques exist to measure the kinetic param-
eters of molecules binding to the protein target of interest. As
GPCRs are integral membrane proteins, biophysical tech-
niques such as surface plasmon resonance which require pu-
rified protein can be challenging and often require mutagene-
sis to stabilise the receptor and allow it to be purified within
lipid micelles or nanodiscs [23, 24]. Techniques that do not
require the receptor to be purified include those that use
radiolabelled or fluorescently labelled ligands [25, 26]. One
limitation of these techniques is that they can only directly
measure the kinetic parameters of the labelled compound. To
overcome this, the methodology proposed by Motulsky and
Mahan is often employed [27]. This technique measures the
association kinetics of a labelled ligand in the presence of an
unlabelled ligand and through knowledge of the kinetic pa-
rameters of the labelled ligand both the association and disso-
ciation rate constants of the unlabelled ligand can be calculat-
ed. This technique is widely used with radiolabelled ligands
and has more recently been successfully applied in combina-
tion with fluorescently labelled ligands in resonance energy
transfer techniques such as time-resolved resonance energy
transfer (TR-FRET) and bioluminescence resonance energy
transfer (BRET) [28, 29].
For the A3AR, two recent studies have used radioligands to
determine the kinetic parameters of unlabelled ligands [30,
31]. In the study by Xia et al., however, the radiolabelled
antagonist ([3H]PSB-11) had to be used at low temperatures
(10 °C) to slow the association rate sufficiently to give enough
resolution to accurately determine the kinetic binding
parameters of unlabelled ligands [30]. Due to this limitation
and the inherent issue of throughput associated with
radioligands [25], there is a need to develop additional
methods to measure kinetic parameters. One way to potential-
ly overcome these issues is through the use of fluorescently
labelled ligand which have increased throughput, and previ-
ous studies have suggested that the fluorescent A3AR antag-
onist CA200645 has a slower association rate than [3H]PSB-
11 [32]. For the A3AR, a number of fluorescently labelled
antagonist probes have been developed based on two structur-
ally distinct antagonists which have been shown to retain high
affinity for the receptor [32–34]. Therefore, in this study, we
have developed a live-cell BRET-based kinetic binding assay
for the A3AR using four different fluorescently labelled an-
tagonists. This assay has then been compared to the
radioligand binding assay described in Xia et al. [30] for the
determination of the kinetic binding parameters of unlabelled
ligands.
Material and methods
Materials
Foetal calf serum (FCS) was obtained from PAA Laboratories
(Wokingham, UK). Furimazine was purchased from Promega
(Southampton, UK). Bicinchoninic acid protein assay kit and
white 96-well microplates were obtained from Thermo Fisher
Scientific (Waltham, MA, USA). GF/B filter plates and
Microscint-O were from PerkinElmer (Groningen,
The Netherlands). CA200645 was obtained from HelloBio
(Bristol, UK). The synthesis of AV039 was described in
Vernall et al. as compound 19 [34], while the synthesis of
XAC-S-ser-S-tyr-X-BY630 (compound 27) and XAC-S-ser-
S-tyr-X-BYFL (compound 28) was described in Vernall et al.
2013 [33]. PSB-11 and MRS1220 were purchased from
Tocris Bioscience (Bristol, UK), and NECA was obtained
from Sigma-Aldrich (Zwijndrecht, The Netherlands). [3H]8-
Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-
imidazo[2,1-i]-purin-5-one ([3H]PSB-11) was kindly donated
by Prof. C.E. Müller (University of Bonn, Germany) and its
synthesis described inMüller et al. [35]. 1-Benzyl-8-methoxy-
1H,3H-pyrido[2,1-f]purine-2,4-dione (compound 5) synthesis
was described in Priego et al. as compound number 3 [36] and
referred in Xia et al. [37] as compound number 5, while
LUF7565 synthesis was described in Xia et al. as compound
27 [30]. All other chemicals and reagents were obtained from
Sigma-Aldrich (Gillingham, UK).
Cell culture and membrane preparation
Generation of human embryonic kidney 293 (HEK293) cells
stably expressing the human A3AR tagged at the N-terminus
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with NanoLuc (Nluc-A3AR) is described in Stoddart et al.
[38], and these cells were used throughout this study. Nluc-
A3ARHEK293 cells were maintained in Dulbecco’s modified
Eagle’s medium containing 10% FCS and 2 mM L-glutamine
at 37 °C, 5% CO2.
For membrane preparation, Nluc-A3AR HEK293 cells
were grown to confluence in 500-cm2 dishes. Normal growth
media was replaced with ice-cold PBS, and the cells were
removed from the dish using a cell scraper. The cells were
then transferred to a 50-ml tube and centrifuged at 250×g for
5 min. The supernatant was discarded, and the resulting pellets
were stored at − 80 °C. Thawed pellets were resuspended in
ice-cold PBS and homogenised using an IKA T10 Ultra-
Turrax disperser in 10 × 5 s bursts at 15,000 rpm. After re-
moval of unbroken cells and nuclei by centrifugation at
1200×g for 10 min, the supernatant was centrifuged at
41,415×g for 30 min to obtain the membrane pellet. The pellet
was then resuspended in ice-cold PBS and homogenised by 20
passes using a Kartell serrated pestle and a borosilicate glass
homogeniser mortar fitted to an IKA RW16 overhead stirrer
set to 1000 rpm. Finally, protein concentrationwas determined
using a bicinchoninic acid protein assay [37] and membranes
stored at − 80 °C until needed.
NanoBRET binding assays
HEK293 cells stably expressing human Nluc-A3AR were
seeded in normal growth medium 24 h prior to experimenta-
tion in white 96-well microplates coated with poly-D-lysine
(100 μg/ml poly-D-lysine in PBS, 30 min room temperature,
then washed in normal growth medium prior to use).
Immediately before experimentation, media was replaced
with HEPES buffered saline solution (HBSS; 145 mmol/L
NaCL, 5 mmol/L KCl, 1.7 mmol/L CaCl2, 1 mmol/L
MgSO4, 10 mmol/L HEPES, 2 mmol/L sodium pyruvate,
1.5 mmol/L NaHCO3, 10 mmol/L D-glucose, pH 7.4). For
saturation and competition binding assays, the required con-
centration of fluorescent ligand and competing ligand was
added simultaneously and incubated for 1 h (for AV039) or
3 h (for XAC-S-ser-S-tyr-X-BY630) at 37 °C (no CO2). After
1 h, 10 μM furimazine was added to each well and the plate
incubated for 5 min at 37 °C before reading. Prior to all kinetic
experiments, the medium was replaced by HBSS containing
10 μM furimazine and incubated at room temperature in the
dark for 15 min to allow the luminescence signal to reach
equilibrium [29]. For association kinetic experiments, follow-
ing the furimazine incubation, the required concentration of
fluorescent ligand in the presence or absence of 10 μM
MRS1220 was added simultaneously and the plate read im-
mediately once per minute for up to 3 h at 37 °C. For kinetic
competition association assays, after furimazine incubation,
either XAC-S-ser-S-tyr-X-BY630 (20 nM) or AV039
(40 nM) were added simultaneously with the required
concentration of unlabelled ligand or 10 μM MRS1220 to
determine non-specific binding and read once per minute for
the indicated times at 37 °C. For all NanoBRET experiments,
fluorescence and luminescence were read using a PHERAstar
FS plate reader (BMG Labtech, Ortenberg, Germany).
Filtered light emissions were measured at 460 nm (80 nm
band pass) and at > 610 nm (long pass) for the BY630 labelled
ligands and at 450 nm (80 nm band pass) and > 550 nm (long
pass) for the BYFL labelled ligand. The raw NanoBRET ratio
was calculated by dividing the fluorescence emission (610 or
550 nm) by the luminescence emission (460 or 450 nm).
Radioligand binding assays
Prior to all experiments, membranes from HEK293
membranes expressing human Nluc-A3AR were diluted
to 20 μg/well in a total volume of 100 μL/well assay
buffer (50 mM Tris-HCl, 5 mM MgCl2, supplemented
with 0.01% CHAPS and 1 mM EDTA, pH 7.4) and
homogenised using an IKA T10 Ultra-Turrax disperser
in 3 × 5 s bursts at 15,000 rpm. For equilibrium dis-
placement assays, membranes were placed in 96-well
microplates at 10 °C and the required concentration of
competing agonist was added in the presence of a final
concentration of ~ 10 nM [3H] PSB-11 with nonspecific
binding determined in the presence of 100 μM NECA
(final concentration). For association assays, Nluc-A3AR
HEK293 membranes were placed at 10 °C in 96-well
microplates and the amount of radioligand bound to the
receptor was measured at different time points during a
total incubation of 120 min. For dissociation experi-
ments, HEK293 membranes expressing human Nluc-
A3AR were incubated for 120 min with ~ 10 nM [
3H]
PSB-11 at 10 °C prior the addition of 10 μM PSB-11
(final concentration) at various time points during a fur-
ther 120 min. The competition association assays were
initiated by the addition of Nluc-A3AR HEK293 mem-
branes at different time points for a total of 240 min to
a total volume of 100 μl/well of assay buffer at 10 °C
with ~ 10 nM [3H] PSB-11 in the absence or presence
of a single concentration (2 × Ki) of competing A3AR
ligands. For all experiments, incubation was terminated
by rapid filtration performed on 96-well GF/B filter
plates using a PerkinElmer Filtermate-harvester
(PerkinElmer, Groningen, The Netherlands). After dry-
ing the filter plate at 50 °C for 30 min, the filter-bound
radioactivity was determined by scintillation spectrome-
t r y u s i ng a 2450 Mic roBe t a 2 P l a t e Coun t e r
(PerkinElmer, Boston, MA). In addition, the exact con-
centration of [3H] PSB-11 used in each experiment was
determined by scintillation spectrometry and this con-
centration was used in the data analysis.
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Data analysis
All experimental data were analysed using Prism7 (GraphPad
Software, San Diego, CA).
NanoBRET total and non-specific saturation binding
curves were fitted simultaneously using the following equa-
tion:
BRET ratio ¼ Bmax: B½ 
B½  þ KD þ M : B½ ð Þ þ Cð Þ
where Bmax is the maximal specific binding achieved, [B] is
the concentration of fluorescent ligand, KD is the equilibrium
dissociation constant, M is the slope of the non-specific bind-
ing component and C is the intercept with the Y-axis.
Equilibrium competition binding curves were fitted with
the following equation:
K i ¼ IC50
1þ L½ 
KD
where [L] is the concentration of [3H]PSB11, AV039 or XAC-
S-ser-S-tyr-X-BY630 and KD is the equilibrium dissociation
constant of the labelled ligand (9.9 nM for [3H]PSB-11,
14.5 nM for XAC-S-ser-S-tyr-X-BY630 and 32.5 nM for
AV039 as determined in saturation binding assay performed
as part of this study). The IC50 is obtained as follows:
%inhibition of specific binding ¼ 100: A½ 
A½  þ IC50
where [A] is the concentration of unlabelled competing drug
and IC50 is the molar concentration of this competing ligand
required to inhibit 50% of the specific binding of the concen-
tration [L] of the labelled ligand.
For NanoBRETassociation kinetic data, non-specific bind-
ing was determined in wells with fluorescent ligand plus
10 μM MRS1220 and this was obtained for each concentra-
tion of fluorescent ligand at each time point. This was subse-
quently subtracted from total binding at the equivalent time
point. The data were simultaneously fit to the following equa-
tions:
Y ¼ Ymax 1−e−kobst
 
kon ¼ kobs−koffL½ 
where Ymax equals the level of binding at infinite time (t), kobs
is the rate constant for the observed rate of association at a
particular concentration of L, [L] is the ligand concentration in
molar, koff is the dissociation rate constant of the ligand in per
minute and kon is the association rate constant in per molar per
minute. From this, the equilibrium dissociation constant (KD)
is determined as follows:
KD ¼ koffkon
The binding kinetics of unlabelled ligands was quantified
using the competition association assay based on the theoret-
ical framework byMotulsky andMahan [27]. NanoBRETand
radioligand data were fitted into the competition association
model using ‘kinetics of competitive binding’ to determine
association and dissociation rate constants of the unlabelled
compounds:
KA ¼ k1 L½ ⋅10−9 þ k2
KB ¼ k3 I½ ⋅10−9 þ k4
S ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
KA−KBð Þ2 þ 4⋅k1⋅k3⋅L⋅I ⋅10−18
q
K F ¼ 0:5 KA þ KB þ Sð Þ
KS ¼ 0:5 KA þ KB−Sð Þ
Q ¼ Bmax⋅k1⋅L⋅10
−9
K F−KS
Y ¼ Q⋅ k4⋅ K F−KSð Þ
K F ⋅KS
þ k4−K F
K F
e −K F ⋅Xð Þ−
k4−KS
KS
e −KS ⋅Xð Þ
where k1 is the kon of the labelled ligand (M
−1 min−1), k2 is the
koff of the labelled ligand (min
−1), L is the concentration of the
labelled ligand in nanomolar, I is the concentration of the
unlabelled competitor (nM), X is the time (min) and Y is the
specific binding of the labelled ligand (NanoBRET ratio or
DPM).
k1 and k2 values were generated from association kinetic
experiments. k3, k4 and Bmax were then calculated, where k3
represents the kon (M
−1 min−1) of the unlabelled ligand, k4
stands for the koff (min
−1) of the unlabelled ligand and Bmax
equals the total binding (NanoBRET ratio or DPM). The res-
idence time (RT) was calculated as the reciprocal of the ligand
dissociation rate constant as follows:
RT ¼ 1
koff
Statistical significance was determined by Student’s un-
paired t test where p < 0.05 was considered statistically signif-
icant throughout this study.
Results
NanoBRET binding profile of fluorescent probes
at Nluc-A3AR in live cells
The four fluorescent ligands used in this study have previously
been shown to display high affinity for the A3AR, and their
structures are shown in Fig. 1 [32–34]. Three of the ligands
are based on the non-selective adenosine receptor antagonist
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xanthine amine congener (XAC). Two of these XAC linked
compounds contain a serine, tyrosine dipeptide (both in the S
configuration) to link the pharmacophore to the fluorophore
which is either BODIPY630/650 (excitation max 630 nm, emis-
sion max 650 nm) to give XAC-S-ser-S-tyr-BY630 (Fig. 1a, or
BODIPY-FL (excitation max 503 nm, emission max 512 nm) to
give XAC-S-ser-S-tyr-BYFL (Fig. 1b) [33]. The third XAC-
based compound, CA200645 (Fig. 1c), contains a polyamide
linker (β-alanine, β-alanine) connected to the BY630
fluorophore [32]. AV039 (Fig. 1d) is based on the A3AR selec-
tive antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one linked to
BY630 and has been shown to retain A3AR selectivity [34].
Initially, we determined the affinity of each of these fluo-
rescent antagonists at NanoLuc tagged A3AR (Nluc-A3AR) in
the NanoBRETassay. An advantage of NanoBRETcompared
to radioligand binding experiments is the large concentration
range of fluorescent ligands over which binding can be mea-
sured, and to represent this accurately, binding is fitted as a
sigmoidal curve with BRET ratio values plotted versus the log
concentration of fluorescent ligand. In all the cases, we obtain-
ed a saturable curve clearly dependent on the concentration of
the fluorescent ligands (Fig. 2). Non-specific binding was de-
termined by co-incubation with 10 μM of the unlabelled high
affinity A3AR antagonist MRS1220, and all four fluorescent
Fig. 1 Structures of the A3AR fluorescent (a–d) and unlabelled (e–g) antagonists used in this study
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ligands exhibited very low levels of non-specific NanoBRET
in line with previously published NanoBRET data [29, 38].
The point on the curve which gives the 50% of the binding
was then taken as KD. The pKD values calculated for the four
fluorescent antagonists are shown in Table 1. All four ligands
displayed high affinities for Nluc-A3AR which were consis-
tent with literature values, and the range of pKD values were
found to span less than 1 log unit (pKD 7.78–8.11).
To determine the kinetic parameters of fluorescent ligands
at the A3AR, Nluc-A3AR expressing HEK293 cells were ini-
tially treated with the Nanoluc substrate, furimazine (10 μM),
for 15 min prior to the fluorescent ligand to allow the lumi-
nescence signal to stabilise as described previously [29].
Increasing concentrations of fluorescent ligands were then
added and the change in NanoBRET monitored at 37 °C over
time, with specific binding determined in the presence of the
high affinity A3AR antagonist MRS1220 (10 μM) for every
time point (Fig. 3). The kinetic parameters obtained from
globally fitting the association curves showed that all four
fluorescent ligands had similar association rates within a fac-
tor of two of each other (Table 1). As expected, the range of
dissociation rates for AV039, CA200645 and XAC-S-ser-S-
tyr-X-BYFL were also within a factor of two of each other,
leading to similar RTs. The dissociation rate for XAC-S-ser-S-
tyr-X-BY630, however, was over ten times slower than that of
the other three fluorescent ligands. This produced a markedly
different RT for XAC-S-ser-S-tyr-X-BY630 which was of the
order of hours (4.8 h) compared to the muchmore rapid values
Fig. 2 Determination of the
binding affinity of four
fluorescent antagonists at human
A3AR. NanoBRET saturation
binding curves obtained by
treating Nluc-A3AR HEK293
cells with increasing
concentrations of the fluorescent
antagonists AV039 (a),
CA200645 (b), XAC-S-ser-S-tyr-
X-BYFL (c) or XAC-S-ser-S-tyr-
X-BY630 (d) in the absence
(black circles) or presence (red
squares) of 10 μM MRS1220 for
1 h at 37 °C. The data shown are
mean ± SEM and are
representative of five independent
experiments each performed in
triplicate
Table 1 Kinetic parameters and binding affinities of fluorescent antagonists at the human A3AR measured by NanoBRET
Kinetics Equilibrium saturation
Compound pKD kon (× 10
6) (M−1 min−1) koff (min
−1) RT (min) n pKD n
AV039 7.35 ± 0.10* 3.67 ± 0.62 0.15 ± 0.02 6.8 ± 0.8 4 8.11 ± 0.10* 5
CA200645 7.58 ± 0.04* 2.58 ± 0.05 0.069 ± 0.006 14.8 ± 1.1 5 7.80 ± 0.07* 5
XAC-S-ser-S-tyr-X-BY630 8.57 ± 0.15 1.66 ± 0.36 0.0043 ± 0.0009 288 ± 62 5 8.51 ± 0.07 5
XAC-S-ser-S-tyr-X-BYFL 7.75 ± 0.14 3.95 ± 0.73 0.069 ± 0.006 14.9 ± 1.1 4 7.78 ± 0.05 5
Saturation pKD values were calculated directly from the saturation binding curves of the fluorescent ligands binding to Nluc-A3AR HEK293 cells. The
kinetic parameters, kon, koff and pKD values, were obtained bymonitoring the NanoBRETsignal over time of various concentrations of fluorescent ligand
in HEK293 Nluc-A3AR cells at 37 °C. The residence time (RT) was calculated as the reciprocal of the koff values from each individual experiment. All
values represent mean ± SEM from n separate experiments performed in triplicate
*p < 0.05, kinetic versus equilibrium saturation pKD values according to unpaired Student’s t test
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(min) obtained for the other three compounds. Additionally, it
can be noted that the pKD values from saturation studies of
XAC-S-ser-S-tyr-X-BY630 and XAC-S-ser-S-tyr-X-BYFL
are comparable to those obtained from the kinetic data, where-
as for CA200645 and AV039, the saturation pKD values are
significantly higher than the kinetic pKD (Table 1, p < 0.05,
unpaired t test).
Radioligand binding characterisation of fluorescent
probe
To confirm the differences in the kinetics observed with
AV039 and XAC-S-ser-S-tyr-X-BY630, radioligand equilibri-
um and kinetic binding assays in membranes from HEK293
cells stably expressing Nluc-A3AR were undertaken. Initially,
the binding affinity and kinetic parameters of the radiolabelled
A3AR antagonist [
3H]PSB-11 at Nluc-A3AR were resolved
from its association and dissociation curves at 10 °C
(Fig. 4a, b; Table 2) and were similar to those obtained previ-
ously with the wild-type A3AR [30]. Next, the ability of XAC-
S-ser-S-tyr-X-BY630 and AV039 to compete at equilibrium
with specific [3H]PSB-11 binding to the Nluc-A3AR was ex-
amined (Fig. 4c) and the pKi for each of these compounds
determined (Table 2). The affinities obtained in the
radioligand binding assay for both fluorescent probes were
lower than those obtained in the NanoBRET experiments
(Table 1), which may reflect differences in affinity values
determined in whole cells compared to cell membranes, and
also the impact of temperature (10 °C versus 37 °C), as pre-
viously observed for the histamine H1 receptor [29].
The association and dissociation rates of XAC-S-ser-S-tyr-
X-BY630 and AV039 were determined in kinetic association
assays where the specific binding of [3H]PSB-11 in the pres-
ence and absence of a single concentration (2 × IC50) of the
fluorescent ligand was monitored over time and the resulting
data fitted to the model proposed by Motulsky and Mahan
[27]. As expected from the kinetic behaviour observed in the
NanoBRET assay, the association curve of [3H]PSB-11 ob-
tained in the presence of AV039 quickly reached an equilibri-
um plateau (Fig. 4d) indicating that AV039 has a similar or
faster kinetic profile compared to [3H]PSB-11. This was borne
out in the kinetics parameters obtained from fitting the data to
the Motulsky and Mahan model (Table 2). In comparison,
XAC-S-ser-S-tyr-X-BY630 induced an ‘overshoot’ in
[3H]PSB-11 specific binding followed by a steady decrease
(Fig. 4e) which is characteristic of long RT compounds. As
such, both the association and dissociation rate constants of
this fluorescent ligand are more than 10 times slower than
those of AV039, whilst the pKD values are very similar. As a
consequence, it was confirmed that XAC-S-ser-S-tyr-X-
BY630 had a long RT (over 7.5 h) compared to AV039 and
[3H]PSB-11.
Fig. 3 Association kinetics of four fluorescent antagonists at human
A3AR. After 15 min pre-incubation with 0.5 μM furimazine, Nluc-
A3AR HEK293 cells were treated with the indicated concentrations of
CA200645 (a), AV039 (b), XAC-S-ser-S-tyr-X-BYFL (c) or XAC-S-ser-
S-tyr-X-BY630 (d) and the NanoBRET signal was monitored at 37 °C
every min for 60 min (a–c) or 180 min (d). The data shown are mean ±
SEM and are representative examples from four (a, c) or five (b, d)
independent experiments, each performed in triplicate
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Determination of the affinity and kinetic constants
of unlabelled ligands
To extend the use of the NanoBRET binding assay, it is nec-
essary to use this setup to determine the kinetics of unlabelled
ligands using the Motulsky and Mahan approach. To demon-
strate its utility, it is important that the NanoBRET assay can
distinguish between fast and slow unlabelled compounds.
First, it was important to select unlabelled compounds with
the desired kinetic profile. Using [3H]PSB-11 as the tracer, the
kinetic parameters of two previously described high-affinity
A3AR antagonists, compound 5 [36] (Fig. 1e) and LUF7565
[30] (Fig. 1f) were determined at Nluc-A3AR. Competition
binding experiments indicated compound 5 and LUF7565
Fig. 4 Radioligand binding characterisation of fluorescent probes at
human A3AR. Association (a) and dissociation (b) curves of 10 nM
[3H]PSB-11 in Nluc-A3AR HEK293 membranes performed at 10 °C.
Dissociation of the radioligand was initiated by addition of 10 μM
PSB-11 after equilibrium had been reached at 2 h. Data were
normalised to the maximal [3H]PSB-11 labelling in each experiment
and shown as the mean and S.E.M. of five independent experiments
performed in duplicate. c Nluc-A3AR membranes were treated with
increasing concentrations of AV039 (squares) and XAC-S-ser-S-tyr-X-
BY630 (circles) and 10 nM [3H]PSB-11 in HEK293 Nluc-A3AR
membranes at 10 °C to generate competition binding curves. Data were
normalised to the maximal specific [3H]PSB-11 labelling in each
experiment. Data points are combined mean ± SEM from five separate
experiments performed in duplicate. d, e Competition association time
course of ~ 10 nM [3H]PSB-11 on HEK293 Nluc-A3AR membranes at
10 °C in either absence (control, black circles) or presence of a single
concentration (2 ×Ki value) of AV039 (d, red squares) or XAC-S-ser-S-
tyr-X-BY630 (e, red squares). The data shown are representative
examples from four (d) and five (e) independent experiments performed
in duplicate with each data point shown
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gave a concentration-dependent inhibition of the specific
binding of [3H]PSB-11 with LUF7565 displaying higher
affinity for Nluc-A3AR than compound 5 (Fig. 5a; Table 2).
The association and dissociation rate constants of compound 5
Table 2 Radioligand binding affinities and kinetic parameters of fluorescent probes and unlabelled ligands at the human A3AR
Kinetics Equilibrium competition
pKD kon (× 10
6 M−1 min−1) koff (min
−1) RT (min) n pKi n
[3H]PSB-11 8.04 ± 0.08 2.75 ± 0.52 0.023 ± 0.002 44.6 ± 3.9 5 ND ND
AV039 7.63 ± 0.08 3.27 ± 0.47 0.076 ± 0.009 14.0 ± 1.6 5 7.65 ± 0.02 5
XAC-S-ser-S-tyr-X-BY630 7.74 ± 0.08* 0.14 ± 0.04 0.0023 ± 0.0002 447 ± 44 4 7.21 ± 0.06* 5
compound 5 7.53 ± 0.13 6.61 ± 1.76 0.198 ± 0.045 6.5 ± 2.1 4 7.35 ± 0.02 5
LUF7565 9.11 ± 0.04* 8.17 ± 0.95 0.0065 ± 0.0014 168 ± 25 4 8.99 ± 0.02* 5
pKi values were calculated from inhibition of equilibrium [
3H]PSB-11 binding to Nluc-A3AR HEK293 membranes at 10 °C. The kinetic parameters,
kon, koff and pKD values of PSB-11 were obtained from association and dissociation curves of 10 nM [
3H]PSB-11 in Nluc-A3ARHEK293membranes at
10 °C. Radioligand dissociation was initiated by the addition of 10 μM unlabeled PSB-11. The kinetic parameters, kon, koff and pKD values of AV039,
XAC-S-ser-S-tyr-X-BY630, compound 5 and LUF7565 were obtained by competition association with ~ 10 nM [3H]PSB-11 at 10 °C. The RT was
calculated as the reciprocal of the koff values from each individual experiment. All values represent mean ± SEM from n separate experiments performed
in duplicate
ND not determined
*p < 0.05, kinetic pKD versus equilibrium competition pKi values according to unpaired Student’s t test
Fig. 5 Radioligand binding characterisation of unlabelled ligands at
human A3AR. a HEK293 membranes expressing human Nluc-A3AR
were treated with increasing concentrations of compound 5 (red
triangles) and LUF7565 (green squares), and 10 nM [3H]PSB-11 at
10 °C for 2 h and levels of [3H]PSB-11 binding monitored by
scintillation counting. Data were normalised to the maximal specific
[3H]PSB-11 labelling in each experiment. Data points are combined
mean ± SEM from five separate experiments performed in duplicate. b,
c Association of [3H]PSB-11 on Nluc-A3AR HEK293 membranes at
10 °C in the absence (control, black circles) or presence of a single
concentration (2 ×Ki value) of and LUF7565 (b) or compound 5 (c).
The data shown are representative examples from four independent
experiments performed in duplicate with each data point shown
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and LUF7565 were then determined from the decrease in the
specific binding of [3H]PSB-11 in the presence of a single
concentration (2 × IC50) of the unlabelled ligands. The com-
petition association curve of compound 5 (Fig. 5c) exhibited
the kinetic profile of a short RT ligand, while LUF7565 in-
duced an ‘overshoot’ in the [3H]PSB-11-specific binding (Fig.
5b) which is the characteristic profile of a long RTcompound,
and this was confirmed from the calculated kinetic parameters
(Table 2). Radioligand kinetic affinity was comparable to that
obtained by radioligand displacement for both the unlabelled
ligands.
The selective A3AR fluorescent antagonist AV039 was
chosen as a short RT probe to evaluate the affinity and kinetic
parameters of compound 5, LUF7565 alongside those of PSB-
11. Initially, the affinity of these three antagonists was deter-
mined in an equilibrium competition assay using 20 nM
AV039 in HEK 293 cells stably expressing the Nluc-A3AR
(Fig. 6a; Table 3). As expected, all three ligands exhibited
high affinity for the A3AR, confirming the data obtained using
[3H]PSB-11. To further investigate the properties of these
compounds, their binding kinetic parameters were determined
using AV039 as the probe. The time-dependent decrease in the
association binding of AV039 induced by the addition of dif-
ferent concentrations of PSB-11, compound 5 and LUF7565
was monitored at 37 °C (Fig. 6b–d) to determine the kinetic
parameters of these unlabelled compounds. The competition
association curves of PSB-11 (Fig. 6b) and compound 5 (Fig.
6c) exhibited the typical kinetic profile of a short RT ligand,
while LUF7565 (Fig. 6d) induced a very pronounced initial
overshoot in binding of AV039 followed by a decrease which
is characteristic of a long RTcompound. As expected from the
shape of the competition association curves, LUF7565 was
found to have the slowest dissociation rate and subsequently
the longest RT (Table 3). The kinetic pKD of the short RT
compounds PSB-11 and compound 5 was similar to the equi-
librium pKi, while for the slow dissociation compound
LUF7565, the kinetic pKD was significantly higher than pKi
(p < 0.05, unpaired t test).
As XAC-S-ser-S-tyr-X-BY630 was found to have a con-
siderably longer RT than AV039 and [3H]PSB-11, it was used
to investigate the effect of the RT and binding kinetic param-
eters of the labelled probe on the measured kinetic parameters
of unlabelled ligands. Firstly, it was confirmed that PSB-11,
compound 5 and LUF7565 inhibited the specific XAC-S-ser-
S-tyr-X-BY630 binding in a concentration-dependent manner
in Nluc-A3AR HEK 293 cells (Fig. 7a; Table 3). It was noted
that the affinity obtained for all the compounds was around
half a log unit lower than the pKi value obtained with AV039,
Fig. 6 Characterisation of the effect of unlabelled ligands on the binding
of AV039 to Nluc-A3AR using NanoBRET (a). Nluc-A3AR cells were
treated with 50 nM AV039 and increasing concentrations of PSB-11
(black circles), compound 5 (red triangles) and LUF7565 (green
squares) for 1 h at 37 °C and competition binding curves generated.
Data were normalised to the maximal BRET signal in each experiment.
Data points are combined mean ± SEM from five separate experiments
performed in triplicate. b–d After 15 min pre-incubation with 0.5 μM
furimazine, the association rate of 40 nM AV039 was monitored, via
NanoBRET, at 37 °C in HEK293 cells expressing human Nluc-A3AR
in the absence (control, black circles) or presence of the indicated
concentrations of PSB-11 (b), compound 5 (c) and LUF7565 (d). The
data shown are representative examples from five (b, c) or six (d)
independent experiments performed in triplicate, and the depicted data
points represent the mean ± SEM of the triplicates
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but exhibited the same trend, with PSB-11 displaying the
highest affinity at A3AR and compound 5 the least potent.
The concentration-dependent decrease in the association
binding of XAC-S-ser-S-tyr-X-BY630 induced by the addi-
tion of different concentrations of PSB-11, compound 5 and
LUF7565 allowed us to determine the association and disso-
ciation rates of these unlabelled compounds when using a long
RT compound as the probe. The competition association
curves obtained in the presence of all three unlabelled ligands
showed a continuous increase in XAC-S-ser-S-tyr-X-BY630
signal parallel to that observed with the fluorescent ligand
only (Fig. 7b–d). Only a small initial overshoot in binding
was observed in the presence of 100 and 300 nM of
LUF7565. The kinetic parameters obtained for all ligands
are presented in Table 3. The kinetic pKD for compound 5
and PSB-11 was similar to that obtained at equilibrium, while
LUF7565’s kinetic pKD was slightly higher than the equilib-
rium pKi. In comparison to the kinetic parameters obtained
with AV039, the kon values were lower when using XAC-S-
ser-S-tyr-X-BY630 as the probe for all three unlabelled com-
pounds. For PSB-11 and compound 5, an increase in RT was
observed with XAC-S-ser-S-tyr-X-BY630 in comparison to
that with AV039, whereas a decrease in the RT of LUF7565
was seen.
Discussion
It is becoming increasingly clear that a ligand’s binding kinet-
ics are a crucial part of its pharmacology which can play a role
in its success in the clinic [16, 18, 20]. In this study, we set out
to develop an assay to determine the kinetic parameters of
molecules binding to the A3AR using NanoBRET in living
cells and at physiological temperatures. We also compared the
values obtained to those obtained in a more classical
radioligand binding assay that used cell membrane prepara-
tions and was performed at much lower temperatures (10 °C).
We found that kinetic parameters of unlabelled ligands obtain-
ed in both assays were comparable when using a labelled
probe with similar kinetics (AV039 versus [3H]PSB-11).
Moreover, when a long RT probe (XAC-S-ser-S-tyr-X-
BY630) was used, it was difficult to resolve the differences
in kinetic parameters of a fast and slow unlabelled compound.
This indicates that the kinetic profile of the labelled probe can
influence the range of kon and koff values that can be accurately
determined.
For many years, the toolbox available for studying binding
kinetics at GPCRs was limited to the use of radioligand bind-
ing assays [14]. With the increasing range of fluorescent li-
gands available for the study of GPCRs alongside more suit-
able proteins for use in energy transfer techniques (such as
NanoLuc and SNAP), there has been increased interest in
adapting these techniques to measure ligand-binding kineticsTa
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[26]. Here, we have developed a BRET-based kinetic assay for
the A3AR. This is particularly important for the A3AR, as
historically there has only been a radiolabelled agonist com-
mercially available, and radiolabelled antagonists, such as the
one used in this study, have to be custom synthesised [35]. The
A3AR offered a unique opportunity for this since multiple
fluorescent ligands based on different parent molecules have
been described in the literature and one of these ligands is
commercially available [32–34]. Three of these fluorescent
ligands measured in this study were based on the non-
selective adenosine receptor antagonist XAC. Two of these
ligands, CA200645 and XAC-S-ser-S-tyr-X-BYFL, were
found to have similar kon and koff rate constants, whereas
XAC-S-ser-S-tyr-X-BY630 had a similar value for kon but a
much slower koff rate constant. In the development of fluores-
cent ligands with improved imaging properties, incorporation
of a peptide linker between the pharmacophore and
fluorophore was found to prevent the ligand from crossing
the cell membrane in a non-specific manner [29, 33].
Molecular modelling has suggested that this linker region
makes additional contacts at the top of the transmembrane
domains of the receptor and that the fluorophore is buried
within the lipid environment of the plasma membrane [33].
This has also been observed in molecular modelling of fluo-
rescent ligands binding to the histamine H1 receptor [29].
Other studies that have developed fluorescent ligands have
also found that the fluorophore can influence the affinity of
the resulting molecule [39, 40]. It is therefore clear that the
fluorophore portion of fluorescent ligand is not a passive part
of the molecule but can influence both the affinity and binding
kinetics. The chemical structures of XAC-S-ser-S-tyr-X-
BY630 and XAC-S-ser-S-tyr-X-BYFL are very similar and
only differ in the structure of the fluorophore. It has previously
been shown with the β2-adrenoceptor that the interaction of
ligands with the membrane influences the observed associa-
tion rates [41]. The interaction of a ligand with a membrane
can create a micro-environment which can alter the observed
kinetic profiles [42]. It is possible that the BODIPY
fluorophores interact differently with the cell membrane to
increase the RT of XAC-S-ser-S-tyr-X-BY630 compared to
XAC-S-ser-S-tyr-X-BYFL. It is worth noting, however, that
the mere presence of a BY630 fluorophore is not a determi-
nant for a longer RT compound since both CA200645 and
AV039 contain the same fluorophore.
The availability of a radiolabelled antagonist, [3H]PSB-11,
allowed us to compare the kinetic parameters of unlabelled
ligands, measured using either long or short RT fluorescent
ligand in the NanoBRET assay, with those obtained in a more
traditional radioligand binding assay. We found that the kon
rate constants measured with all three unlabelled ligands were
Fig. 7 Characterisation of the effect of unlabelled ligands on the binding
of XAC-S-ser-S-tyr-X-BY630 to Nluc-A3AR using NanoBRET. a Nluc-
A3AR cells were treated with 40 nM XAC-S-ser-S-tyr-X-BY630 and
increasing concentrations of PSB-11 (black circles), compound 5 (red
triangles) and LUF7565 (green squares) for 3 h at 37 °C and competition
binding curves generated. Data were normalised to the maximal BRET
signal in each experiment. Data points are combined mean ± SEM from
five (PSB-11) or six (compound 5 and LUF7565) separate experiments
performed in triplicate. b–d The association of 20 nM XAC-S-ser-S-tyr-
X-BY630 on HEK293 cells expressing human Nluc-A3AR at 37 °C was
monitored at the indicated times byNanoBRET in either absence (control,
black circles) or presence of various concentrations of compound 5 (b),
PSB 11 (c) and LUF7565 (d). The data shown are representative
examples from four (b, c) or five (d) independent experiments performed
in triplicate, and the depicted data points represent the mean ± SEM of the
triplicates
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all within a similar range (Table 2) although the rank order
within data sets was not the same. For example, LUF7565was
found to have the fastest association rate when either
[3H]PSB-11 or XAC-S-ser-S-tyr-X-BY630 were used as the
probe, whereas LUF7565 had the slowest association rate
when measured against AV039. Although here we have only
compared the kinetic parameters of three compounds, this is
similar to previous studies comparing the kinetic parameters
of GnRH ligands determined using radioligand binding and
time-resolved FRET (TR-FRET) where no correlation be-
tween association rates was found in the two assay setups [43].
In comparison to the tight range of kon values, there was a
wider range of measured koff values. For both [
3H]PSB-11 and
AV039, there was between a 30- and 94-fold difference, re-
spectively, in the koff values measured for compound 5 and
LUF7565, with LUF7565 displaying the slowest koff of the
measured unlabelled compounds using both probes. This in-
dicates that for both these probes, a wide range of kinetic
parameters can be measured. As seen in Fig. 7, the profile of
the competition association curves with each of the three
unlabelled compounds was comparable, and this is reflected
in the similarities in the kinetic parameters obtained. To date,
LUF7565 is one of the longest residence time unlabelled li-
gands reported at A3AR, and it may be that XAC-S-ser-S-tyr-
X-BY630 will be a useful tool to find even longer RT com-
pounds at this receptor.
Although a similar trend was seen for the koff values
determined using [3H]PSB-11 and AV039, 10-fold
higher koff values were determined for PSB-11 and com-
pound 5 when using AV039, leading to compounds with
apparently shorter RT. There are many differences in
setup of the two assays which could lead to these dif-
ferences and need to be kept in mind when comparing
the data sets. One of the main differences is that the
radioligand binding assay uses membrane preparations,
whereas the BRET assays are performed on intact cells.
The intact cell environment preserves all of the intracel-
lular proteins that a GPCR can interact with, and these
are known to be able to stabilise different conformations
of the receptor which in turn may affect the binding
kinetics of the ligands [44, 45]. As these interacting
proteins include G proteins and arrestins, preservation
of the intact cellular environment allows downstream
signalling and internalisation to still occur. It is unlikely
that internalisation plays a role in this study since XAC-
S-ser-S-tyr-X-BY630 and AV039 have previously been
shown to be competitive antagonists, and in confocal
imaging studies, there was no indication that these li-
gands caused internalisation of the A3AR [33, 34].
Although it appears that these fluorescent ligands do
not cause internalisation of the receptor, it is possible
that the antagonist bound form of the receptor may in-
teract with different adaptor proteins and this may
underpin some of the differences observed. Differences
in binding kinetics have also been observed previously
when comparing measurements from membrane prepara-
tions and whole cells at other GPCRs including the
dopamine D2L receptor [46] and histamine H1 receptor
[29]. For the D2L receptor, it was suggested that differ-
ences in dissociation rates are a reflection of how the
ligand interacts with the cell membrane [46]. Apart
from receptor environment, the two assay setups were
performed at different temperatures—radioligand binding
at 10 °C and BRET at 37 °C—and it can be assumed
from basic thermodynamic principles that both associa-
tion and dissociation rates will increase with tempera-
ture. Due to the rapid kinetics of [3H]PSB-11, the com-
petition association assay is challenging to perform at
higher temperature [30], and since the plate reader used
for the live cell assay lacks the capacity to be actively
cooled, we are unable at the present time to directly test
this. An increase in association and dissociation rate
with temperature has been observed for the histamine
H1 receptor [47] and the prolactin receptor [48].
In summary, this study has demonstrated that a
NanoBRET-based assay can be applied to measure ligand-
binding kinetics at the A3AR in intact living cells at physio-
logical temperatures. The data shown here do, however, indi-
cate that care needs to be taken when selecting a probe with
the appropriate kinetics for the study of unlabelled ligands
with different kinetic profiles. Thus, probes with very slow
kinetics may be problematic for the determination of the ki-
netic parameters of unlabelled ligands with rapid kinetic prop-
erties. As the range of fluorescent ligands for GPCRs con-
tinues to expand [49], their use in NanoBRET-based assays
should provide the required diversity of kinetic properties to
evaluate the kinetic profiles of the broadest range of
unlabelled ligands in a physiologically relevant setting.
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